暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
自选模拟交易
美股期权个股详情
ANAB241220P12500
- 1.12
- -0.03-2.61%
延时15分钟行情收盘价 11/26 16:00 (美东)
1.37最高价1.12最低价
1.35今开1.15昨收108张成交量1013张未平仓合约数12.50行权价1.41万成交额284.79%隐含波动率54.93%溢价2024/12/20到期日0.00内在价值100合约乘数23天距到期日1.12时间价值100合约规模美式期权类型-0.0906Delta0.0089Gamma23.49杠杆倍数-0.0630Theta-0.0020Rho-2.13有效杠杆0.0105Vega
分时
- 5日
- 日K
新闻
对anaptysbio的ANB032持谨慎乐观态度：在疗效不确定性中的有望临床前数据
AnaptysBio公司（纳斯达克：ANAB）45%的下跌仍使一些股东对其市销率感到不安
AnaptysBio公司（纳斯达克:ANAB）的股价在过去一个月里表现得非常糟糕，大幅下跌了45%。尽管如此，糟糕的一个月并没有完全毁掉过去一年的股市表现。
经纪人对AnaptysBio, Inc. (纳斯达克:ANAB）的营业收入预测正在迅速上升
Anaptysbio, Inc.2024财年第三财季实现净利润-32.85百万美元，同比增加11.95%
摩根大通维持anaptysbio股票评级为超重
anaptysbio被JP评为超配
AnaptysBio（纳斯达克:ANAB）是否在冒险地使用债务？
由Berkshire Hathaway的Charlie Munger支持的外部基金经理Li Lu毫不掩饰地说：“最大的投资风险不在价格波动，而在于你是否
评论
$AnaptysBio (ANAB.US)$ looking good got smacked last timee it tested $40.. needs to break that on heavy volume 🤔
$AnaptysBio (ANAB.US)$
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...
1
$AnaptysBio (ANAB.US)$
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
1
$Travere Therapeutic (TVTX.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$美国联合医疗 (UTHR.US)$ Phase 3
$美国联合医疗 (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$乌龙制药 (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...
$CG Oncology (CGON.US)$ Phase 3
$美国联合医疗 (UTHR.US)$ Phase 3
$美国联合医疗 (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$乌龙制药 (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...
19
阅读更多